Accueil   Diary - News   All news Poxel Presents Complete PXL770 Phase 1 Results

Poxel Presents Complete PXL770 Phase 1 Results

Poxel Presents Complete PXL770 Phase 1 Results, Cardiac Safety Profile and Preclinical Efficacy Data in NASH at AMPK - From Mechanisms to New Therapies Scientific Congress

 

  • Phase 1 clinical program for PXL770 was observed to have a favorable pharmacokinetic, tolerability and safety profile
  • PXL770 was observed to have a favorable cardiac safety profile in both healthy subjects and in animal models
  • PXL770 was observed to show efficacy in a diet-induced obese-NASH mice model

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree